Targeted Treatment in Asthma-Opportunities and Challenges
Ioana Agache, Magdalena Zemelka-Wiacek, Radosław Gawlik, Steve N Georas, Karina Jahnz-Różyk, Maciej Kupczyk, Marcin Moniuszko, Ralph Mӧsges, Manali Mukherjee, Parameswaran Nair, Alberto Papi, Marek Sanak, Ali Ӧnder Yildirim, Marek Jutel, CSEA3 Expert Group
Share post:
Abstract
This review summarizes the key insights and future directions on targeted asthma treatment discussed during the 2025 Expert Meeting supported by the Central and Southern European Allergy and Asthma Alliance (CSEA3). Targeted treatment in asthma is becoming an attainable goal for selected patients but is not yet established as a standard asthma care pathway. The expert panel identified 4 key priorities to advance targeted asthma management:
(1) Defining remission-a universally accepted, evidence-based definition is needed to guide clinical practice and guideline development. (2) The management of mild asthma guided by patient stratification according to asthma pathogenetic pathways (endotype) and risk profile may enable more tailored therapy and better outcomes.
(3) Biomarker discovery and validation-research must prioritize predictive biomarkers that are easy to measure at the point of care, supported by innovative trials that combine precision immunology and machine learning.
(4) Optimizing implementation and addressing the barriers to adopting stratified care, including limited resources and cost-effectiveness concerns, must be addressed. Digital tools offer promise but require further validation. Coordinated efforts are essential to translate advances in personalized asthma treatment into better outcomes and more sustainable care, particularly in resource-limited settings.
